CARLSBAD, CA -- (MARKET WIRE) -- August 31, 2006 -- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that it has entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited, a private investment group. Under the terms of the agreement, Kingsbridge has committed to provide up to $25 million of capital during the next three years through the purchase of newly-issued shares of Micromet’s common stock. Micromet will determine the timing and amount of any CEFF financings, subject to certain conditions.
